Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th.

Cytosorbents Price Performance

Shares of Cytosorbents stock opened at $1.01 on Thursday. The firm has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $1.02. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $2.15. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The company has a market cap of $55.23 million, a PE ratio of -2.81 and a beta of 0.57.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently bought and sold shares of the business. Sargent Investment Group LLC raised its stake in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares in the last quarter. Atomi Financial Group Inc. bought a new stake in Cytosorbents in the third quarter valued at about $51,000. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, CM Management LLC lifted its stake in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.